PFS as an Endpoint in Ovarian Cancer Trials

Video

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

Clinical Pearls

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

  • It is difficult to get a new drug in ovarian cancer approved based on OS data
Recent Videos
Related Content
Top 10 Breast Cancer Breakthroughs in 2024

Top 10 Breast Cancer Breakthroughs in 2024

Jordyn Sava
December 23rd 2024
Article

Here are the top 10 developments from the year.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

Luspatercept: A Challenge to Erythropoietin and Its Role in Boosting QOL in MDS

Luspatercept: A Challenge to Erythropoietin and Its Role in Boosting QOL in MDS

Targeted Oncology Staff
December 20th 2024
Article

Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

The Promise of Metabolomics to Transform Breast Cancer Screening

The Promise of Metabolomics to Transform Breast Cancer Screening

Morgan Bayer
December 19th 2024
Article

One new frontier of cancer detection is emerging: metabolomics.

Read More

FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC

FDA Issues CRL for SC Amivantamab BLA in EGFR+ NSCLC

Jordyn Sava
December 18th 2024
Article

The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing manufacturing inspection issues, but confirming no need for additional clinical trials.

Read More